Tests for Coronary artery disease

  1. ๐Ÿ“š Citations
  2. ๐Ÿฆ  Taxons (Bacteria) report by studies
  3. ๐Ÿฅฃ Candidates for improving (avoids and takes)
  4. ๐Ÿ”ฎ Bacteria Related Conditions
  5. es-xenogene is located in Spain and is expensive compared to others

Some 16s providers support download of FASTQ (raw data - BIG FILES). These can be processed thru other services (at the moment, Thryve and Biomesight offers free processing). The bacteria is determine by computer algorithms, which differs from lab to lab.

  1. Biomesight and BiomeSightRdp ships worldwide - including the US
  2. Thryve is now Ombre Labs but only ships to the US
  3. CosmosId is available thru NirvanaBiome
  4. Medivere is based in Germany
  5. American Gut
  6. Xenogene is both the most expensive and most detail for rare bacteria. They are based in Spain
  7. uBiome is no longer in business
The Percentage of significant bacteria each test reports on
Name Percentage
Thryve 93.1%
FASTQ processed thru both Thryve and BiomeSight 93.1%
SequentiaBiotech 82.8%
CosmosId 79.3%
BiomeSightRdp 75.9%
bugspeak 72.4%
Tiny 69%
uBiome 69%
Thorne 65.5%
es-xenogene 62.1%
BiomeSight 62.1%
CerbaLab 58.6%
Medivere 55.2%
Microba 51.7%
AmericanGut 51.7%
Gut Zoomer (vibrant-wellness) 37.9%
Microba1 31%
GanzimmunDiag 31%
Metagenomics Stool (De Meirleir) (16s Limited) 27.6%
Biovis Microbiome Plus (cfu/g) 17.2%
GI360 Stool (UK) 17.2%
Genova Gi Effects (cfu/g) 13.8%
DayTwo 13.8%
GanzImmun Diagnostic A6 (cfu/gm) 13.8%
Medivere Mikrobiom Plus Stuhlanalyse 13.8%
Viome (Latest Reports Fail to provide ANY measurements) 10.3%
Smart Gut (ubiome 16s - Limited Taxonomy) 6.9%
Diagnostic Solution GI-Map (cfu/gm) 6.9%
GI EcologiX (Invivo) 6.9%
Bioscreen (cfu/gm) 3.4%
GanzImmun Diagnostics AG Befundbericht 3.4%
Medivere: Darm Mikrobiom Stuhltest (16s limited) 3.4%
Nordic Laboratories 3.4%

All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.

Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 ยงโ€ฏ1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.

The awesome web hosting site that we use. Try it if you need to host (or unhappy with current provider)